EC approves first-line ovarian cancer treatment
A Phase III trial evaluating rucaparib demonstrated that it significantly…
A Phase III trial evaluating rucaparib demonstrated that it significantly improved progression-free survival in women with advanced ovarian cancer, regardless of their BRCA mutation status.